Latest News
Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical, Inc. Estimates – HAM:UP0
- Form DEF 14A Ultragenyx Pharmaceutical Inc For: 21 October
- Form 4 Ultragenyx Pharmaceutical Inc: Howard Horn (CFO) For: 15 October
- Ultragenyx Pharmaceutical Enters Settlement With Navinta Over Dojolvi
- Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
- Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building
- Ultragenyx’s second PRV sale; Biomea’s oral GLP-1 data leads to stock slump
- Ultragenyx to sell rare PRV for $210 million
- Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher | PharmExec
- Ultragenyx to Sell Rare Pediatric Disease Voucher for $210 Million
- Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
- Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize
Headlines from the last 30 days, linking to the original publishers. See all market news →